Prostate News and Research

RSS

Call for UK and Luxembourg governments to put access to quality cancer treatment at the top of their health agendas

Speaking today at a workshop on 'Cancer treatment: a priority for patients in Europe', cancer specialists and representatives of cancer patients called on the UK and Luxembourg governments to put access to quality cancer treatment at the top of their health agendas during their Presidencies of the EU in 2005.

7 Oct 2004

Breast cancer drug Taxotere extends life of prostate cancer patients

Men with androgen-independent (hormone-refractory) metastatic prostate cancer treated with the breast-cancer drug Taxotere (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy

6 Oct 2004

$10 million to establish a multidisciplinary research program in cancer nanotechnology

The National Institutes of Health (NIH) has awarded scientists from Emory University and the Georgia Institute of Technology two new collaborative research grants, totaling nearly $10 million, to establish a multidisciplinary research program in cancer nanotechnology and to develop a new class of nanoparticles for molecular and cellular imaging.

6 Oct 2004

Study suggests that radiation oncologists can and should be more aggressive in their treatment of prostate cancer

Increasing the radiation dose delivered by highly conformal external beam radiation to men suffering from early stage prostate cancer shows an advantage in terms of increased disease-free survival rates

5 Oct 2004

3 year study to validate bladder cancer test

A three-year study to validate a test to detect the recurrence of bladder cancer has been initiated by the National Cancer Institute (NCI), at 12 centers across the United States and Canada.

4 Oct 2004

Race influences participation in clinical trials

Caucasian and non-Caucasian cancer patients are equally interested in learning about clinical trials. However, non-Caucasian patients are less likely to enroll in a trial unless the chances are high that it would benefit them

4 Oct 2004

New national resource for medical researchers to be known as the Center on Proteolytic Pathways

The National Institutes of Health (“NIH”) has selected The Burnham Institute to develop a national resource for medical researchers to be known as the “Center on Proteolytic Pathways”.

4 Oct 2004

Lycopene may be able to inhibit the growth of prostate tumours

A study by Dutch and German researchers has provided evidence that lycopene may be able to inhibit the growth of prostate tumours and that its effect may be enhanced if it is combined with vitamin E.

30 Sep 2004

Researchers show gossypol – a drug refined from cottonseed oil is a cancer treatment booster

New research has opened up the prospect that gossypol – a drug refined from cottonseed oil and previously tried and abandoned as a male contraceptive – could boost the effectiveness of treatment for prostate tumours and possibly other common cancers as well.

30 Sep 2004

Male smokers needed for study to investigate new method of improving selenium intake

Around 200 men – including men who smoke – are being sought by researchers in Adelaide, South Australia to take part in a new study aimed at preventing cancer and other health problems.

30 Sep 2004

Black men in the United States are significantly less likely to be screened for prostate cancer

Although black men in the United States are more likely than white men to be diagnosed with advanced prostate cancer and have a two-fold greater risk of dying from it, they are significantly less likely to be screened for prostate cancer

29 Sep 2004

Cancer vaccine based on listeria bacteria shows promise

An experimental cancer vaccine using defanged listeria bacteria is showing great promise in animal studies, successfully treating new cancers that have spread into the lungs of mice.

29 Sep 2004

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

28 Sep 2004

Prostate News and Research

Call for UK and Luxembourg governments to put access to quality cancer treatment at the top of their health agendas

Breast cancer drug Taxotere extends life of prostate cancer patients

$10 million to establish a multidisciplinary research program in cancer nanotechnology

Study suggests that radiation oncologists can and should be more aggressive in their treatment of prostate cancer

3 year study to validate bladder cancer test

Race influences participation in clinical trials

New national resource for medical researchers to be known as the Center on Proteolytic Pathways

Lycopene may be able to inhibit the growth of prostate tumours

Researchers show gossypol – a drug refined from cottonseed oil is a cancer treatment booster

Male smokers needed for study to investigate new method of improving selenium intake

Black men in the United States are significantly less likely to be screened for prostate cancer

Cancer vaccine based on listeria bacteria shows promise

Phase II trials of the first second-generation antisense cancer drug to be used in patients soon to be underway

New hope for patients suffering hormone therapy resitant prostate cancer

Prostate cancer treatment leads to declines in sexual and urinary function

Elderly African American men are less likely to get tested for prostate cancer

Four or more glasses of red wine per week may reduce risk of prostate cancer by 50 percent

Stress response proteins offer a promising target for a novel drug guidance system

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News